Complexes of low energy beta emitters 47Sc and 177Lu with zoledronic acid for bone pain therapy

Applied Radiation and Isotopes

Volumn 67, Issue 1, 2009, Pages 11-13

  Majkowska, Agnieszka ^a   Neves, Maria ^b   Antunes, Ines ^b   Bilewicz, Aleksander ^a  

^a INSTITUTE OF NUCLEAR CHEMISTRY AND TECHNOLOGY   (Poland)

^b INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

Author keywords

Bisphosphonates; Targeted radiotherapy; Zoledronic acid

Indexed keywords

ADSORPTION; APATITE; BINDING ENERGY; BONE; HOLMIUM; HYDROXYAPATITE; LUTETIUM; RADIOISOTOPES; RADIOTHERAPY; SCANDIUM;

ABSORBED DOSES; ADSORPTION EXPERIMENTS; BETA EMITTERS; BISPHOSPHONATE; BISPHOSPHONATES; BONE MARROWS; BONE RESORPTIONS; HEALTHY TISSUES; LOW ENERGIES; LOW ENERGY ELEC-TRONS; RADIO-NUCLIDES; SIDE CHAINS; TARGETED RADIOTHERAPY; ZOLEDRONIC ACID; ZOLEDRONIC ACIDS;

ACIDS;

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HOLMIUM; HOLMIUM 166; HYDROXYAPATITE; LUTETIUM 177; NERIDRONIC ACID; PAMIDRONIC ACID; RADIOISOTOPE; SAMARIUM 153; SCANDIUM; SCANDIUM 47; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADSORPTION; ARTICLE; BINDING AFFINITY; BONE PAIN; CANCER RADIOTHERAPY; COMPLEX FORMATION; DRUG TARGETING; ISOTOPE LABELING; ONCOLOGY; OSTEOLYSIS; PRIORITY JOURNAL; RADIATION DOSE; RADIOCHEMISTRY; TARGETED RADIOTHERAPY;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; IMIDAZOLES; LUTETIUM; PAIN; RADIOISOTOPES; SCANDIUM;

EID: 56349103173     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2008.08.014     Document Type: Article

References (12)

1. Bouchet L.G., Bolch W.E., Goddu S.M., Howell R.W., and Rao D.V. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J. Nucl. Med. 41 (2000) 682-687
2. Firestone R.B., Shirley V.S., and Lederer C.M. Table of Isotopes. eighth ed (1996), Wiley, New York
3. Fleisch H. Bisphosphonates: mechanisms of action. Endocr. Rev. 19 (1998) 80-100
4. Josse S., Faucheux C., Soueidan A., Grimandi G., Massiot D., Alonso B., Janvier P., Laib S., Pilet P., Gauthier O., Daculsi G., Guicheux J., Bujoli B., and Bouler J.M. Novel biomaterials for bisphosphonate delivery. Biomaterials 26 (2005) 2073-2080
5. Louw W.K.A., Dormehl I.C., van Rensburg A.J., Hugo N., Alberts A.S., Forsynth O.E., Beverly G., Sweetlove M.A., Marais J., Lotter M.G., and van Aswegen A. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Nucl. Med. Biol. 23 (1996) 935-940
6. 166Ho complexes as potential agents for therapy or bone pain palliation. J. Inorg. Biochem. 100 (2006) 270-280
7. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., Mangood A., Russell R.G.G., and Ebetino F.H. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38 (2006) 617-627
8. Neves M., Gano L., Pereira N., Costa M.C., Costa M.R., Chandia M., Rosado M., and Fausto R. Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nucl. Med. Biol. 29 (2002) 329-338
9. Ogawa K., Mukai T., Arano Y., Otaka A., Ueda M., Uehara T., Magata Y., Hashimoto K., and Saji H. Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. Nucl. Med. Biol. 33 (2006) 513-520
10. Reszka A.A., and Rodan G.A. Bisphosphonate mechanism of action. Curr. Rheumatol. Rep. 5 (2003) 65-74
11. 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones. Nucl. Med. Biol. 34 (2007) 79-87
12. Zeevaart J.R., Jarvis N.V., Louw W.K.A., and Jackson G.E. Metal-ion speciation in blood plasma incorporating the tetraphosphonate, N,N-dimethylenephosphonate-1-hydroxy-4-aminopropilydenediphosphonate (APDDMP), in therapeutic radiopharmaceuticals. J. Inorg. Biochem. 83 (2001) 56-65